Clinical Trials
26 trialsExploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
National Institutes of Health Clinical Center (CC)
Rare CNS Tumors Outcomes &Risk
National Institutes of Health Clinical Center (CC)
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Carboplatin and Bevacizumab for Recurrent Ependymoma
National Institutes of Health Clinical Center (CC)
Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers
National Institutes of Health Clinical Center (CC)
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
National Cancer Institute (NCI)
Stereotactic Radiosurgery in Treating Patients With Brain Tumors
National Institutes of Health Clinical Center (CC)
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors
National Institutes of Health Clinical Center (CC)
Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma
National Institutes of Health Clinical Center (CC)
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
National Cancer Institute (NCI)
CC-5013 in Treating Patients With Recurrent Glioma
National Cancer Institute (NCI)
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
National Cancer Institute (NCI)
Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma
National Cancer Institute (NCI)
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma
National Cancer Institute (NCI)
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
National Cancer Institute (NCI)
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
National Institutes of Health Clinical Center (CC)
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Carmustine in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)
O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)